GSK beat third-quarter earnings forecasts on Wednesday and raised its 2022 estimate for the second time in four months, continuing its strong start as a standalone prescription medicine business since spinning off its consumer health unit.
Tag Archive for: Pfizer
Australia’s CSL Ltd. said on Wednesday it had struck a licensing deal with Arcturus Therapeutics Holdings Inc. that would help it gain access to the U.S. drug developer’s messenger RNA (mRNA) vaccine technology.
Pfizer Inc. on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.
Pfizer Inc. said on Tuesday its experimental respiratory syncytial virus (RSV) vaccine was found effective for preventing severe infections in infants after being given in a late-stage study to expectant mothers in the second half of pregnancy.
U.S. officials are working on a respiratory syncytial virus (RSV) vaccine, but until one is available people should exercise caution, especially seniors and parents of young children, the nation’s top infectious disease official said.
Reports of heavy periods – bleeding characterized by increased volume and/or duration that interferes with the quality of life – have been observed during clinical trials, from cases in the real world and in medical literature, according to the European Medicines Agency.
The U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc.’s antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday.
Italy’s tax authorities are investigating profits reported by Pfizer Inc.’s local unit Pfizer Italia srl, two sources with knowledge of the matter told Reuters on Thursday.
Pfizer’s attempt to as much as quadruple its current U.S. prices for its COVID-19 vaccines going forward could spur revenues for years, analysts said.
Pfizer Inc. expects to roughly quadruple the price of its COVID-19 vaccine to about $110 to $130 per dose after the United States government’s current purchase program expires, Pfizer executive Angela Lukin said on Thursday.
